Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects With Moderate to Late Stage Parkinson's Disease Who Are Also Receiving Treatment With Levodopa.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Sep 2019
Price :
$35
*
At a glance
- Drugs Vipadenant (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- 06 May 2011 Actual end date (31 Dec 2007) added as reported by ISRCTN: Current Controlled Trials.
- 13 Jun 2010 Efficacy outcomes have been presented at the 14th International Congress of Parkinson's Disease and Movement Disorders.
- 21 Apr 2010 Tolerability outcomes have been presented at AAN 2010.